Stockreport

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

Alkermes plc - Ordinary Shares  (ALKS) 
Last alkermes plc - ordinary shares earnings: 4/29 07:00 am Check Earnings Report
PDF — Alixorexton Data From Seven-Week Open-Label Extension Period Demonstrated Sustained Improvements in Patient-Reported Disease Severity, Cognitive Functioning and Fatigu [Read more]